Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III beta-tubulin levels

FEBS Lett. 2008 Jan 23;582(2):267-72. doi: 10.1016/j.febslet.2007.12.014. Epub 2007 Dec 18.

Abstract

We have previously shown that Docetaxel-induced variable degrees of apoptosis in melanoma. In this report, we studied the beta-tubulin repertoire of melanoma cell lines and show that class III beta-tubulin expression correlated with Docetaxel-resistance. Sensitive cells showed low levels of class III beta-tubulin with little microtubular incorporation, whereas class III beta-tubulin expression was higher in resistant cells and was incorporated into the cytoskeleton. As proof of concept, abrogation of class III by siRNA reverted Docetaxel-resistant cells to a sensitive phenotype, restoring the microtubular polymerisation response and promoting high levels of apoptosis through Bax activation. These results suggest that phenotypic expression of beta-tubulin class III in melanoma may help identify patients with melanoma that can respond to taxanes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects*
  • Cell Line, Tumor
  • Docetaxel
  • Flow Cytometry
  • Humans
  • Melanoma / metabolism
  • Melanoma / pathology*
  • RNA, Small Interfering
  • Taxoids / pharmacology*
  • Tubulin / metabolism*

Substances

  • Antineoplastic Agents
  • RNA, Small Interfering
  • Taxoids
  • Tubulin
  • Docetaxel